AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12538197 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 2 mg (Group II, n=60)
Number of subjects: 206
Study 12538197 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 80 mg (Group III, n=82)
Number of subjects: 206
Study 10815751 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine intravenous infusion
Number of subjects: 10
Study 10815751 — intervention group
Group type: COMPARATOR
Intervention: Isradipine oral administration
Number of subjects: 10
Study 8843933 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to computer services (experimental group)
Number of subjects: 179
Study 8843933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to computer services)
Number of subjects: 179
Study 1739343 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at third month of life
Number of subjects: 0
Study 1739343 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination at birth
Number of subjects: 0
Study 6496012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg diazepam (4-5 min prior)
Number of subjects: 587
Study 6496012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg diazepam (8-10 min prior)
Number of subjects: 587
Study 6496012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg diazepam (4-5 min prior)
Number of subjects: 587
Study 6496012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg diazepam (8-10 min prior)
Number of subjects: 587
Study 6496012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg d-tubocurarine (4-5 min prior)
Number of subjects: 587
Study 6496012 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 587
Study 6496012 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam-pretreated groups (0.05 mg/kg and 0.1 mg/kg)
Number of subjects: 587
Study 6496012 — intervention group
Group type: EXPERIMENTAL
Intervention: d-tubocurarine pretreatment
Number of subjects: 587
Study 29476763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting into half
Number of subjects: 25
Study 29476763 — intervention group
Group type: EXPERIMENTAL
Intervention: Grinding
Number of subjects: 25
Study 29476763 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushing
Number of subjects: 25
Study 29476763 — intervention group
Group type: COMPARATOR
Intervention: Whole film-coated bilayer tablets (reference)
Number of subjects: 25
Study 26607935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS-PLs) 20 g/d, 118 kcal
Number of subjects: 4011
Study 23464746 — intervention group
Group type: EXPERIMENTAL
Intervention: N2 O/O2 inhalation
Number of subjects: 56
Study 23195001 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus plus telmisartan
Number of subjects: 16
Study 23195001 — intervention group
Group type: COMPARATOR
Intervention: telmisartan (control)
Number of subjects: 16
Study 20018523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile cardiopulmonary bypass (PCPB)
Number of subjects: 60
Study 20018523 — intervention group
Group type: COMPARATOR
Intervention: Linear cardiopulmonary bypass (LCPB)
Number of subjects: 60
Study 20018523 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCABG)
Number of subjects: 60
Study 18813045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-based anesthesia (n = 25)
Number of subjects: 59
Study 18813045 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthesia (control, n = 34)
Number of subjects: 59
Study 15947284 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion during hypoxia in HAPE-S subjects
Number of subjects: 18
Study 15947284 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (HAPE-R) during hypoxia
Number of subjects: 18
Study 15947284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery systolic pressure in HAPE-S subjects during hypoxia
Number of subjects: 18
Study 15947284 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery systolic pressure in control subjects during hypoxia
Number of subjects: 18
Study 15947284 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ACh infusion response with pulmonary artery systolic pressure in HAPE-S subjects
Number of subjects: 18
Study 15947284 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma nitrite with ACh-induced vasodilation in HAPE-S subjects
Number of subjects: 18
Study 12895199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination oral contraceptive (40 microg ethinyloestradiol and 75 microg LNG)
Number of subjects: 10
Study 12895199 — intervention group
Group type: COMPARATOR
Intervention: LNG alone (60 microg)
Number of subjects: 10
Study 12895199 — intervention group
Group type: COMPARATOR
Intervention: Combination oral contraceptive and LNG alone
Number of subjects: 10
Study 10480766 — intervention group
Group type: COMPARATOR
Intervention: Insulin Dosage Guide
Number of subjects: 143
Study 10480766 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Dosage Guide with rapid-acting insulin
Number of subjects: 143
Study 10480766 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Dosage Guide with insulin pump
Number of subjects: 143
Study 7574000 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanethidine
Number of subjects: 60
Study 7574000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1940126 — intervention group
Group type: EXPERIMENTAL
Intervention: vigabatrin
Number of subjects: 34
Study 1940126 — intervention group
Group type: COMPARATOR
Intervention: carbamazepine
Number of subjects: 34
Study 7024883 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-platinum
Number of subjects: 100
Study 31677711 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (40 mg/day)
Number of subjects: 4
Study 31677711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (50,000 IU/15 days)
Number of subjects: 4
Study 31677711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both soy isoflavones and cholecalciferol
Number of subjects: 4
Study 31677711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 28195374 — intervention group
Group type: EXPERIMENTAL
Intervention: Weakly bent molecules with peripheral core substitution
Number of subjects: 0
Study 28195374 — intervention group
Group type: COMPARATOR
Intervention: Weakly bent molecules with inside-directed fluorination
Number of subjects: 0
Study 28195374 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-crystalline phases
Number of subjects: 0
Study 25324332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received eight cookies daily (11.5 g protein; 244 kcal) for 6 weeks.
Number of subjects: 175
Study 25324332 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard institutional diet without cookies.
Number of subjects: 175
Study 25324332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received cookies.
Number of subjects: 175
Study 20569099 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg mifepristone administered 24 hours prior to sample collection
Number of subjects: 9
Study 20569099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mifepristone administered)
Number of subjects: 9
Study 19667028 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 703
Study 19667028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study 17953377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Verapamil (group III)
Number of subjects: 50
Study 17953377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Fentanil + Verapamil (group IV)
Number of subjects: 50
Study 17953377 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (general)
Number of subjects: 50
Study 17953377 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection analgesia (group V)
Number of subjects: 50
Study 15040558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ) 15 mg/kg in a single oral dose
Number of subjects: 143
Study 15040558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (MQ-AS) combination therapy (MQ 15 mg/kg plus AS 4 mg/kg daily for 3 days)
Number of subjects: 143
Study 15040558 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (MQ) alone
Number of subjects: 143
Study 15040558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (MQ-AS) combination therapy
Number of subjects: 143
Study 14687445 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine orally disintegrating tablets (15-45 mg/day)
Number of subjects: 119
Study 10468082 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.02 U/kg/day for 6 months
Number of subjects: 10
Study 10468082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 10
Study 8586897 — intervention group
Group type: EXPERIMENTAL
Intervention: Water bath hyperthermia (delivered biweekly for 8 weeks)
Number of subjects: 7
Study 8586897 — intervention group
Group type: EXPERIMENTAL
Intervention: Water bath hyperthermia (increased frequency to alternate days for some patients)
Number of subjects: 7
Study 8586897 — intervention group
Group type: EXPERIMENTAL
Intervention: Water bath hyperthermia
Number of subjects: 7
Study 1972381 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam 4 mg
Number of subjects: 60
Study 1972381 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam 6 mg
Number of subjects: 60
Study 1972381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1972381 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.15 mg/kg
Number of subjects: 60
Study 537956 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 537956 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 537956 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0
Study 537956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 0
Study 31518433 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 19
Study 31518433 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 19
Study 28683837 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation system (IMACTIS-CT®)
Number of subjects: 500
Study 28683837 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT guidance
Number of subjects: 500
Study 26409213 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative conditioning procedure pairing unhealthy food with negative affect
Number of subjects: 134
Study 26409213 — intervention group
Group type: COMPARATOR
Intervention: Evaluative conditioning procedure pairing unhealthy food with positive affect
Number of subjects: 134
Study 23410208 — intervention group
Group type: EXPERIMENTAL
Intervention: PD with pylorus preservation
Number of subjects: 89
Study 23410208 — intervention group
Group type: COMPARATOR
Intervention: PD with pylorus resection and complete stomach preservation
Number of subjects: 89
Study 20619394 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic therapy (Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides) for 2 days preoperatively and 2 weeks postoperatively
Number of subjects: 50
Study 20619394 — intervention group
Group type: COMPARATOR
Intervention: Control group without synbiotic therapy
Number of subjects: 50
Study 19596057 — intervention group
Group type: EXPERIMENTAL
Intervention: PXM generic formulation (LaborMed Pharma, Romania)
Number of subjects: 24
Study 19596057 — intervention group
Group type: COMPARATOR
Intervention: Feldene (Pfizer, USA)
Number of subjects: 24
Study 17763612 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC moisturizing cream
Number of subjects: 36
Study 17763612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium sulfacetamide 10% lotion
Number of subjects: 36
Study 17763612 — intervention group
Group type: EXPERIMENTAL
Intervention: Jar clindamycin 1%/benzoyl peroxide 5% gel
Number of subjects: 36
Study 17763612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube clindamycin 1%/benzoyl peroxide 5% gel
Number of subjects: 36
Study 15115516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed oral terbinafine (standard dose)
Number of subjects: 42
Study 15115516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed oral terbinafine (double dose)
Number of subjects: 42
Study 11435052 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (10 microg kg(‐1))
Number of subjects: 30
Study 11435052 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (5 microg kg(‐1))
Number of subjects: 30
Study 11435052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9608378 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck support pillows
Number of subjects: 55
Study 30862374 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial disinfectant (persistent disinfectant)
Number of subjects: 0
Study 30862374 — intervention group
Group type: COMPARATOR
Intervention: Dilutable quaternary ammonium agent
Number of subjects: 0
Study 30862374 — intervention group
Group type: COMPARATOR
Intervention: Disinfectant with ethanol and quaternary ammonium
Number of subjects: 0
Study 29424155 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilization
Number of subjects: 67
Study 29424155 — intervention group
Group type: COMPARATOR
Intervention: Routine exercise
Number of subjects: 67
Study 25404551 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritonsillar lornoxicam (8 mg)
Number of subjects: 68
Study 25404551 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bilateral peritonsillar saline infiltration)
Number of subjects: 68
Study 25404551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 68
Study 23313606 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime fluctuations in skin temperature after total sleep deprivation
Number of subjects: 8
Study 19463127 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (stable dose) (n=52)
Number of subjects: 148
Study 19463127 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin titration from 10 to 80 mg/day (n=50)
Number of subjects: 148
Study 19463127 — intervention group
Group type: COMPARATOR
Intervention: Common therapy including lipid lowering drugs (n=46)
Number of subjects: 148
Study 17380211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib (100-400 mg once a day for chronic pain; 400 mg/day for acute pain)
Number of subjects: 0
Study 17380211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Number of subjects: 0
Study 15262691 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% fluorouracil
Number of subjects: 144
Study 15262691 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 144
Study 15262691 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil plus cryosurgery
Number of subjects: 144
Study 15262691 — intervention group
Group type: COMPARATOR
Intervention: Vehicle plus cryosurgery
Number of subjects: 144
Study 11795749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cages
Number of subjects: 0
Study 11795749 — intervention group
Group type: COMPARATOR
Intervention: Allograft or autograft fusion techniques
Number of subjects: 0
Study 9892520 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily)
Number of subjects: 19185
Study 9892520 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg daily)
Number of subjects: 19185
Study 7612056 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride (4.4 mg as tablet, administered b.i.d. on days 4 to 10, single dose on days 1 and 11)
Number of subjects: 14
Study 7612056 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride (4.4 mg as tablet)
Number of subjects: 14
Study 2562605 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (50 micrograms/day)
Number of subjects: 25
Study 2562605 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl oestradiol (20 micrograms/day)
Number of subjects: 25
Study 389037 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Negative Pressure (CNP)
Number of subjects: 36
Study 389037 — intervention group
Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (CPAP)
Number of subjects: 36
Study 31637467 — intervention group
Group type: EXPERIMENTAL
Intervention: AquaCelle® fish oil formulation (SEDDS)
Number of subjects: 0
Study 31637467 — intervention group
Group type: COMPARATOR
Intervention: Control group (unformulated fish oil EE)
Number of subjects: 0
Study 31153838 — intervention group
Group type: COMPARATOR
Intervention: Best Medical Therapy (BMT)
Number of subjects: 2983
Study 31153838 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA plus SET
Number of subjects: 2983
Study 31153838 — intervention group
Group type: COMPARATOR
Intervention: Supervised Exercise Therapy (SET)
Number of subjects: 2983
Study 31153838 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Angioplasty (PTA)
Number of subjects: 2983
Study 28433451 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimmer Natural Nail (ZNN)
Number of subjects: 353
Study 28433451 — intervention group
Group type: COMPARATOR
Intervention: Proximal Femoral Nail Antirotation II (PFNA II)
Number of subjects: 353
Study 25586331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrocaps (FC-002 US)
Number of subjects: 126
Study 25586331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrocaps (FC-002 NL)
Number of subjects: 126
Study 25586331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrocaps
Number of subjects: 126
Study 22805174 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Interruption (TI)
Number of subjects: 106
Study 22805174 — intervention group
Group type: COMPARATOR
Intervention: Continuous Treatment (CT)
Number of subjects: 106
Study 20864621 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of eliglustat tartrate ≤ 20 mg/kg
Number of subjects: 99
Study 20864621 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of eliglustat tartrate ≤ 200 mg bid
Number of subjects: 99
Study 20864621 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses ≥ 10 mg/kg
Number of subjects: 99
Study 20864621 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose pharmacokinetics
Number of subjects: 99
Study 20864621 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose pharmacokinetics
Number of subjects: 99
Study 20864621 — intervention group
Group type: EXPERIMENTAL
Intervention: Food effect on eliglustat tartrate
Number of subjects: 99
Study 19282098 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone at 2.5 mg/day (n=4)
Number of subjects: 15
Study 19282098 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone at 5.0 mg/day (n=5)
Number of subjects: 15
Study 19282098 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone at 7.5 mg/day (n=5)
Number of subjects: 15
Study 19282098 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (all doses)
Number of subjects: 15
Study 17451575 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid gel implantation alone
Number of subjects: 36
Study 17451575 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel followed by laser/RF/IPL treatment
Number of subjects: 36
Study 15367185 — intervention group
Group type: COMPARATOR
Intervention: Prototype E6500 (s1)
Number of subjects: 24
Study 15367185 — intervention group
Group type: COMPARATOR
Intervention: Prototype E6500 (s2)
Number of subjects: 24
Study 15367185 — intervention group
Group type: COMPARATOR
Intervention: Prototype E8000
Number of subjects: 24
Study 15367185 — intervention group
Group type: COMPARATOR
Intervention: Prototype E6500 (s3)
Number of subjects: 24
Study 11137097 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine
Number of subjects: 91
Study 11137097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 10345151 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet/exercise/supplement group (n = 56)
Number of subjects: 123
Study 10345151 — intervention group
Group type: COMPARATOR
Intervention: Diet/exercise/placebo group (n = 67)
Number of subjects: 123
Study 7988320 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustacal administration
Number of subjects: 19
Study 2567127 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (Group F)
Number of subjects: 40
Study 2567127 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 40
Study 31157819 — intervention group
Group type: EXPERIMENTAL
Intervention: CJR model (treatment)
Number of subjects: 157828
Study 31157819 — intervention group
Group type: COMPARATOR
Intervention: non-CJR model (control)
Number of subjects: 157828
Study 28061851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) for malaria in schoolchildren (IPTsc)
Number of subjects: 86
Study 28061851 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for school staff to administer IPT
Number of subjects: 86
Study 28061851 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for health workers over teachers for drug administration
Number of subjects: 86
Study 28061851 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of malaria infection before IPT administration
Number of subjects: 86
Study 26418868 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method and Muscle Energy Technique (MET)
Number of subjects: 60
Study 26418868 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method alone
Number of subjects: 60
Study 26418868 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 60
Study 23499604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) influenza vaccine (Fluzone(®) Intradermal) 9μg HA per strain in 0.1mL
Number of subjects: 4292
Study 23499604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) influenza vaccine
Number of subjects: 4292
Study 23499604 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) influenza vaccine (standard dose) 15μg HA per strain in 0.5mL
Number of subjects: 4292